Brief: Clinuvel Pharmaceuticals Secures IP For Melanocortins To Treat Cns Disorders
14/07/2023 02:11
July 14 (Reuters) - Clinuvel Pharmaceuticals Ltd
CUV.AX :
* CLINUVEL SECURES IP FOR MELANOCORTINS TO TREAT CNS
DISORDERS
* SECURED A FAMILY OF PATENTS AND PATENT APPLICATIONS
RELATING TO
USE OF MELANOCORTIN-BASED MOLECULES
Source text for Eikon: ID:nASX35MP98
Further company coverage: CUV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist